Neutralizing Antibodies and CD8 + T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors (original) (raw)
Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization
Ann Duerr
Journal of Virology, 2010
View PDFchevron_right
Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein
Fred Peyerl
The Journal of Immunology, 2005
View PDFchevron_right
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
Sheri Dubey
Nature Medicine, 2009
View PDFchevron_right
Faculty of 1000 evaluation for Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
Sarah Joseph
F1000 - Post-publication peer review of the biomedical literature, 2009
View PDFchevron_right
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
Birgit Korioth-Schmitz
Journal of Immunology, 2004
View PDFchevron_right
Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset
Bernard Klonjkowski
Vaccine, 2011
View PDFchevron_right
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells
Sarah Ratcliffe
Nature Medicine, 2009
View PDFchevron_right
Effect of Preexisting Immunity on an Adenovirus Vaccine Vector: In Vitro Neutralization Assays Fail To Predict Inhibition by Antiviral Antibody In Vivo
Guangping Gao
Journal of Virology, 2009
View PDFchevron_right
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity
H. kim Lyerly
Cancer Gene Therapy, 2009
View PDFchevron_right
Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity
jaap Goudsmit
Journal of Virology, 2005
View PDFchevron_right
Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions
Lori Maxfield
Journal of Virology, 2012
View PDFchevron_right
Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
Charles Thomas
PLoS ONE, 2012
View PDFchevron_right
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Angela Carville
Nature, 2006
View PDFchevron_right
Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors
Richard Day
Journal of General Virology, 2006
View PDFchevron_right
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Nina Russell
PLoS ONE, 2010
View PDFchevron_right
DNA gag/Adenovirus Type 5 (Ad5) gag and Ad5 gag/Ad5 gag Vaccines Induce Distinct T-Cell Response Profiles
J. Shiver
Journal of Virology, 2008
View PDFchevron_right
Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates
Yue Huang
Journal of Virology, 2005
View PDFchevron_right
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects
Joseph Casazza
PloS one, 2016
View PDFchevron_right
Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles
Daniel Mendoza
PLoS Pathogens, 2011
View PDFchevron_right
Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity
Daniel Appledorn
Clinical and Vaccine Immunology, 2011
View PDFchevron_right
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Ulf Reimer
Journal of Infectious Diseases, 2013
View PDFchevron_right
On the Role of CD4+ T Cells in the CD8+ T-Cell Response Elicited by Recombinant Adenovirus Vaccines
James Millar
Molecular Therapy, 2007
View PDFchevron_right
Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization
Mariano Esteban
The Journal of Immunology, 2013
View PDFchevron_right
Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals
Mary Marovich
Proceedings of the National Academy of Sciences, 2014
View PDFchevron_right
Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys
Angela Carville
Journal of Virology, 2005
View PDFchevron_right
Systemic and Mucosal T-Lymphocyte Activation Induced by Recombinant Adenovirus Vaccines in Rhesus Monkeys
Srinivas Rao
Journal of Virology, 2009
View PDFchevron_right
Effect of Preexisting Immunity to Adenovirus on Transgene Product-Specific Genital T Cell Responses on Vaccination of Mice With a Homologous Vector
Sarah Ratcliffe
Journal of Infectious Diseases, 2011
View PDFchevron_right